Medical breakthroughs can make for major winners in the stock market. For example, Motley Fool points to three biotech stock that could have made millionaires out of Initial Public Offering (IPO) shareholders with small investments. (1)
- $1,250.55 in Amgen Inc.’s (AMGN) IPO
- $1,592.00 in Biogen Inc.’s (BIIB) IPO
- And $8,000 in Gilead Sciences, Inc. (GILD)
As you can see, small investment turned in seven-figures for investors who bought shares in the trio of successful biotechs on IPO day and held on. Of course, these are the exceptions and not the rules, but it’s possible to turn small investments into fortunes if you get lucky and pick the right ones.
Obviously, nobody can promise or guarantee you that any investment is the next AMGN; run from anybody who tells you they can. However, investors can look for upstart medical/drug companies with strong growth prospects and high opinions on Wall Street.
We’ve identified three fast growing companies that Wall Street believes could come close to doubling, maybe more in the next 12-months, according to their consensus price targets.
Sesen Bio, Inc. (SESN)
1 Year Price Target: $7.00 (2)
Current Price: $2.38 (4-14-2021)
Sesen is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. Their lead program, Vicineum™, also known as VB4-845, is currently in a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under rolling review. Vicineum is a locally administered targeted fusion protein composed of an anti-EPCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Highlight: Wall Street sees a big year in 2022 with sales rising 706.40% to $69.67 million from $8.64 million this year. (3)
ThermoGenesis Holdings, Inc. (THMO)
1 Year Price Target: $6.00 (4)
Current Price: $2.63 (4-14-2021)
ThermoGenesis develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.
Highlight: ThermoGenesis has low institutional ownership at only 2.65% with 11.91 million shares outstanding. (5)
Sensus Healthcare, Inc. (SRTS)
1 Year Price Target: $6.71 (6)
Current Price: $3.60 (4-14-2021)
Sensus is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.
Highlight: Sensus trades at 6.06 times sales (7) compared to 7.52 for its peer group.
6 – https://finance.yahoo.com/quote/SRTS?p=SRTS
7 – https://finance.yahoo.com/quote/SRTS/key-statistics?p=SRTS